Cytophage Technologies Ltd.
CYTO.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | |||
|---|---|---|---|---|---|
| Net Income | -4.72% | -5.70% | -270.17% | ||
| Total Depreciation and Amortization | 53.54% | 53.08% | 64.30% | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -118.44% | -105.23% | 104,284.21% | ||
| Change in Net Operating Assets | 62.60% | -34.91% | -794.32% | ||
| Cash from Operations | -2.87% | -111.04% | -122.09% | ||
| Capital Expenditure | -894.78% | -1,018.27% | -198.06% | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -894.78% | -1,018.27% | 37,359.35% | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -85.11% | -164.74% | -170.48% | ||
| Issuance of Common Stock | -100.00% | -98.68% | 1,654.39% | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | 100.00% | -- | ||
| Cash from Financing | -141.76% | -127.67% | -242.13% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -86.34% | -784.87% | 736.54% | ||